Key result
Prior GI ulcer or bleeding is linked to ~26-fold higher gastroprotective co-prescription in aspirin users.
Why the study?
Low-dose aspirin use is associated with serious gastrointestinal adverse effects, but gastroprotective drugs are usually underutilized in these patients.
What is the prescription rate of gastroprotective drugs in patients receiving low-dose aspirin therapy?
Observational (n=303)
No
What is the prescription rate of gastroprotective drugs in patients receiving low-dose aspirin therapy?
Odds Ratio: 26.5
The prescription rate of gastroprotective drugs in patients on low-dose aspirin is low (48.5%), suggesting underutilization and potential lack of awareness regarding aspirin-induced GI complication risk factors.
Supports risk-based gastroprotection in aspirin users; leaves open whether education improves low overall rates.
BACKGROUND: Low-dose aspirin is widely used for prevention of stroke, heart attacks, and death in patients with atherothrombotic disease, but its use is associated with serious gastrointestinal (GI) adverse effects. Gastroprotective drugs (GPDs) have been used to reduce aspirin-related GI complications but are usually underutilized. The aim of this study was therefore to determine the prescription pattern of GPDs with low-dose aspirin therapy. METHODS: All patients who had attended general and specialist outpatient clinics of Tung Wah Hospital between September 1, 2007 and September 30, 2007 and received low-dose aspirin therapy were included in the study. Data were collected through retrospective chart review and recorded on a standardized data collection form. Univariate analysis was performed using chi2 tests for discrete variables. Factors that might be associated with prescription of GPD with low-dose aspirin were assessed in multiple logistic regression models. RESULTS: Three hundred and three patients were included in this study, and the rate of GPD prescription was 48.5%. Most of the patients received H2-receptor antagonist, and, to a lesser degree, antacid and proton pump inhibitor. Patients with history of GI ulcer/bleeding were much more likely to be co-prescribed GPD than those who had no history of GI disorders (OR, 26.5). Compared with patients who were managed in general outpatient clinic, those managed in specialist clinic were more likely to receive GPD (OR, 3.04). CONCLUSION: The prescription rate of GPD with aspirin is low. Also, it seems that physicians are unaware of the risk factors related to aspirin-induced GI complications.
No takes yet. Share an insight, caveat, or question.
Ho-hoi Luk (2009) conducted an observational in Patients receiving low-dose aspirin therapy (n=303). History of GI ulcer/bleeding vs. No history of GI disorders was evaluated on Co-prescription of gastroprotective drugs (GPD) (OR 26.5). A history of GI ulcer or bleeding was strongly associated with the co-prescription of gastroprotective drugs in patients receiving low-dose aspirin (OR 26.5).
Synapse has enriched one closely related paper. Consider it for comparative context: